-
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
•
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced a strategic partnership with MediTrust Health, an insurance, financing, and direct-to-patient pharmacy subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. This collaboration will focus on integrating Grand Pharma’s 90Y product into various commercial insurance schemes, aiming…
-
China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes
•
The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have issued a notification outlining measures to ensure a stable and orderly implementation of urban ‘Huiminbao’ commercial top-up medical insurance schemes. The notice is open for feedback from insurance companies and industry associations nationwide. The document…
-
Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment
•
Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG: 1099), have jointly introduced the first value-based payment (VBP) plan for lymphoma associated with Fosun Kite’s chimeric antigen receptor (CAR) T cell therapy, Yescarta (axicabtagene ciloleucel). Under this innovative plan, eligible patients who do not…
-
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9 million (USD 34 million) in the acquisition of 97.22 million new shares of UnitedHealthcare, securing a 14% stake in the insurance firm. This strategic investment aims to diversify Fosun’s portfolio and enhance its presence in…
